Condition: Extensive Stage Small Cell Lung Cancer · Sponsor: Chugai Pharmaceutical
This study is a phase I, open-label, multicenter trial designed to evaluate the safety, tolerability, pharmacokinetics, immunogenicity, and antitumor activity of ALPS12 in patients with extensive-stage small cell lung cancer. The study consists of two parts: a dose-escalation part and an expansion part.
This description comes directly from the study's public registry record.
Clinical trials information · only use Email · clinical-trials@chugai-pharm.co.jp
Always discuss trial participation with your own doctor first.
| Queen Mary Hospital | Hong Kong, Hong Kong | Recruiting |
| National Cancer Center Hospital East | Kashiwa, Chiba, Japan | Recruiting |
| Ehime University Hospital | Tōon, Ehime, Japan | Recruiting |
| Kindai University Hospital | Sakai, Osaka, Japan | Recruiting |
| Niigata Cancer Center Hospital | Niigata, Japan | Recruiting |
| Show Chwan Memorial Hospital | Changhua, Taiwan | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07107490